Prediction of antibody persistency from antibody titres to natalizumab

Publikation: Bidrag til tidsskriftTidsskriftartikelfagfællebedømt

In a subgroup of patients with multiple sclerosis natalizumab therapy causes generation of anti-natalizumab antibodies that may be transient or persistent. It is recommended to discontinue natalizumab therapy in persistently antibody-positive patients.
OriginalsprogEngelsk
TidsskriftMultiple Sclerosis
Vol/bind18
Udgave nummer10
Sider (fra-til)1493-9
Antal sider7
ISSN1352-4585
DOI
StatusUdgivet - 2012

ID: 48569358